Radar · Neurology in France
Best Neurology Companies in France
The 99 best Neurology companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ethypharm.
By Rohit KhannaTrends & Stories
99companies tracked
$1.1Bdisclosed funding
0unicorns
51have raised
France's Neurology sector is more active than the headlines suggest. This directory ranks 99 tracked companies by disclosed equity funding and recent momentum, with $1.1B in total capital across the cohort. Syremis leads at $165M raised, followed by Ab Science at $83M and Coave Therapeutics at $44M. No unicorns yet, but the funding spread tells you something real: capital is concentrated at the top, and the long tail of sub-$10M companies is still finding its footing. Bpifrance and the EIC Fund are the most visible backers, which tracks with how much of this sector's early-stage oxygen comes from public and quasi-public sources.
The global neurology market sits at roughly $112.5B in 2025 and is forecast to reach $180.2B by 2032 at a 6.9% CAGR, driven by aging demographics and advances in neuroimaging. I'd flag that the hot themes right now, cognitive aging, post-concussion syndrome, and chronic traumatic encephalopathy, are where research attention is compounding fast. As 2015 research on neurological disorders established foundational frameworks still shaping today's clinical pipelines, and the stress-neurology connection is now drawing serious translational interest. Coverage across the French cohort is flat quarter-on-quarter, but the underlying demand drivers are anything but.
Sources & further reading
- biospace.com
FLIAR INTELLIGENCE · NEUROLOGY × FRANCE
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
150kcombined LinkedIn audience
64%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Neurology companies in France
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ethypharm Developer of therapies for the treatment of pain and addiction | $248M | 30 mo ago | Acquired | 1,500 | Aurore Gérigné Co-founder & VP | WordPressApple iCloud MailMySQL+15 | 730 patents Advanced oral dosage forms: low-dose, taste-masked, gastro-retentive, colonic, abuse‑deterrent tablets. | — |
| 2 | Syremis Developer of novel medicines for mental health conditions 22Funding top 20%Global top 45%Talent bottom 49%Tech bottom 29% All 5 signals ▾Fundingtop 20% Globaltop 45% Talentbottom 49% Techbottom 29% Marketbottom 25% Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond France rank vs industry peers · Fliar Intelligence Index 22/100 | $165M | 6 mo ago | Series A | — | Elisabeth Kogan Co-Founder & CEO | WordPressMySQLPHP+15 | — | — |
| 3 | BioSerenity Provider of smart healthcare solutions for sleep and EEG lab management 60Moat top 19%Tech top 25%Patents top 29%Innovation top 34% All 11 signals ▾Moattop 19% Techtop 25% Patentstop 29% Innovationtop 34% Fundingtop 34% Markettop 45% Growthtop 45% Producttop 46% Newsbottom 43% Globalbottom 42% Fin. healthbottom 36% Moat: Editorial + unicorn rating 8/10 · IP moat: 140 patents Tech: 53 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 60/100 | $121M | 31 mo ago | Series B | 340 | — | WordPressApple iCloud MailMicrosoft 365+24 | 140 patents Wearable EEG and physiological monitoring systems with textile and in-ear electrodes | — |
| 4 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 1 mo ago | Public | 3 | — | WordPressPleskMySQL+22 | 461 patents Small-molecule kinase and tubulin inhibitors for oncology and rare disease therapies | — |
| 5 | MedDay Pharmaceuticals Developer of therapeutics for the treatment of neurological and psychiatric diseases | $49M | 122 mo ago | Deadpooled | 82 | — | — | 58 patents Therapeutic biotin and small‑molecule formulations for neurodegenerative and hepatic disorders | — |
| 6 | Coave Therapeutics Developer of gene therapy for ocular and neurological disease 50Funding top 33%Patents top 34%Growth top 35%Moat top 36% All 9 signals ▾Fundingtop 33% Patentstop 34% Growthtop 35% Moattop 36% Innovationtop 42% Talentbottom 49% Techbottom 44% Globalbottom 43% Marketbottom 38% Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 17 mo ago | Series B | 34 | Rodolphe Clerval Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+23 | 27 patents Engineered AAV viral vectors with lactam/squaramide capsid modifications for CNS gene therapy | — |
| 7 | AlgoTx Developer of therapeutic solutions for pain management | $39M | 39 mo ago | Series B | 10 | Olivier Bohuon Founder | — | — | — |
| 8 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 79 mo ago | Public | 29 | Gilles Avenard CEO | Webflow EcommerceWebflowApple iCloud Mail+13 | 58 patents GPVI‑targeted antibodies for anti‑platelet therapy treating cardiovascular disease | — |
| 9 | Robeauté Developer of microrobots for neurosurgical applications 35Growth top 35%Talent top 38%Funding top 44%Global bottom 39% All 6 signals ▾Growthtop 35% Talenttop 38% Fundingtop 44% Globalbottom 39% Techbottom 38% Marketbottom 27% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 17 mo ago | Seed | 15 | Joana Cartocci Co-Founder & COO | WebflowApple iCloud MailMicrosoft 365+8 | — | — |
| 10 | Pharnext Developer of therapeutics for the treatment of neurological diseases | $23M | 75 mo ago | Public | 109 | Daniel Cohen Founder | — | 630 patents Pharmaceutical compositions and combinatorial therapies for neurodegenerative disorders like CMT and Alzheimer. | — |
| 11 | EG 427 Developer of gene therapies for neurogenic bladder 35Talent top 28%Patents top 37%Funding top 38%Moat top 39% All 9 signals ▾Talenttop 28% Patentstop 37% Fundingtop 38% Moattop 39% Innovationtop 48% Globalbottom 43% Marketbottom 33% Techbottom 33% Newsbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $20M | 16 mo ago | Series B | 17 | Pierre Denys Co-Founder | PleskPHPYouTube+11 | 17 patents HSV‑1 based viral gene‑therapy vectors for neurological and bladder disease treatments | — |
| 12 | Alzprotect Developing Tau-protein targeted small molecule drugs for neurodegenerative diseases | $20M | 100 mo ago | Series B | 10 | Philippe Verwaerde CEO | JoomlaPHPYouTube+6 | 71 patents Benzimidazole small‑molecule therapeutics for sensory and motor neuron disease treatment | — |
| 13 | Advicenne Developing paediatrics drugs for CNS and nephrology (including orphan) disorders | $17M | 111 mo ago | Public | 1 | Didier Laurens Chief Executive Officer | WordPressTypeScriptPHP+22 | 42 patents Extended-release oral dosage forms for sultiame and citrate‑based therapies for cystinuria | — |
| 14 | Trophos Research based pharma company focused on developing treatment for spinal muscular atrophy | $16M | 206 mo ago | Acquired | 17 | — | — | 207 patents Cholesterol oxime derivatives and liposomal formulations for pharmaceutical drug delivery | — |
| 15 | Tafalgie Developer of therapeutics for the treatment of chronic postoperative and neuropathic pain 24Growth top 35%Funding top 47%Talent bottom 49%Global bottom 29% All 6 signals ▾Growthtop 35% Fundingtop 47% Talentbottom 49% Globalbottom 29% Techbottom 28% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $14.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 9 mo ago | Series A | — | Eric Schettini Founder & President | WordPress Block EditorWordPressApple iCloud Mail+9 | — | 1 award |
| 16 | Aelis Farma Developer of small molecule drugs targeting CB1 receptor for CNS diseases | $14M | 64 mo ago | Public | 22 | Pier Piazza CEO | Node.jsGSAPVue.js+10 | 61 patents Synthetic pregnane analogs for neuropharmacological treatment of cognitive and cannabinoid disorders | — |
| 17 | Pharmaleads Mid-clinical stage biopharma company developing small molecule therapeutics for chronic pain conditions | $14M | 144 mo ago | Series B | 10 | Dominique Bouvier CEO | — | 198 patents Patents concentrated in health & consumer products | — |
| 18 | YSOPIA Bioscience Developer of microbiome-based therapies for treating diseases like obesity, metabolic, inflammatory & others | $13M | 81 mo ago | Series C | 8 | — | — | — | — |
| 19 | Elkedonia Developer of innovative antidepressant treatment, accessible, fast-acting, and free from dependence. 48Talent top 38%Funding top 44%Global top 45% All 3 signals ▾Talenttop 38% Fundingtop 44% Globaltop 45% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $12.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $13M | 12 mo ago | Seed | — | Delphine Charvin CEO & Co-Founder & Director | — | — | 2 awards |
| 20 | Amonenta Diagnostics Blood-based diagnostic tests for neurodegenerative diseases | $11M | 94 mo ago | Funding Raised | 2 | Huseyin Fırat CEO | — | — | — |
| 21 | MITEM Pharma Developer of targeted therapies to treat multiple diseases | $11M | 49 mo ago | Series B | — | Eric Thierry Co-Founder & COO | — | — | 2 job openings |
| 22 | Hemerion Developer of therapeutic solutions for the treatment of cancer | $7M | 12 mo ago | Series A | 14 | Maximilien Vermandel Co-Founder & CEO | WordPress Block EditorWordPressMySQL+28 | — | 1 partnership |
| 23 | Seabelife Developer of small-molecule drugs that simultaneously inhibit necroptosis and ferroptosis 37Talent top 28%Growth top 35%Patents top 42%Moat top 42% All 10 signals ▾Talenttop 28% Growthtop 35% Patentstop 42% Moattop 42% Innovationbottom 49% Techbottom 47% Fundingbottom 46% Newsbottom 42% Globalbottom 35% Marketbottom 24% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $6M | 8 mo ago | Seed | 8 | Marie-Therese Dimanche-Boitrel Co-Founder | WordPress Block EditorElementorWordPress+25 | 10 patents Regulated necrosis and ferroptosis inhibition therapeutics for tissue regeneration | — |
| 24 | Biodol Therapeutics Developer of therapeutic solutions for treating chronic neuropathic pain | $5M | 69 mo ago | Series A | 8 | Fabien Granier Co-Founder & CEO | — | 23 patents FLT3 kinase inhibitor heteroaryl benzamide compounds for targeted cancer therapy | — |
| 25 | Rest Therapeutics Developer of therapeutics for the treatment of neurological and psychiatric disorders | $5M | 25 mo ago | Funding Raised | 6 | Gilles Rubinstenn Founder & CEO | — | 19 patents Neuroprotective small‑molecule drugs and acetylcholinesterase‑inhibitor combos for neurodegeneration | 1 award |
| 26 | X-Pressure Provider of a medical device to measure cerebrospinal fluid pressure to diagnose brain diseases | $5M | 35 mo ago | Series A | 3 | Eric Schmidt Co-Founder | — | 2 patents Electro‑medical diagnostic and measurement devices for patient monitoring | 1 launch |
| 27 | ORPHELIA Pharma Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology | $4M | 78 mo ago | Acquired | 9 | Hugues Bienayme Founder & CEO | — | — | — |
| 28 | Rebrain Developer of therapeutics for the treatment of neurodegenerative diseases | $4M | 27 mo ago | Seed | 4 | Emmanuel Cuny Co-Founder | WordPressMySQLPHP+14 | — | 1 award |
| 29 | Neurinnov Developer of active implantable medical devices to restore the function of the hand | $3M | 54 mo ago | Seed | 10 | David Andreu Co-Founder | — | 31 patents Implantable closed-loop neural stimulation with interleaved pulses and distributed bus communication | — |
| 30 | Julier Medical Developer of a medical device to treat acute ischemic stroke | $3M | 40 mo ago | Seed | 4 | Laurent Grandidier Co-Founder | — | — | — |
| 31 | Lys Therapeutics Developer of therapeutics for neurological disorders | $3M | 43 mo ago | Seed | 8 | Manuel Blanc Co-Founder & CEO | — | — | — |
| 32 | BrainEver Developer of drug candidates to treat neurodegenerative diseases | $3M | 48 mo ago | Funding Raised | 17 | Bernard Gilly Co-Founder & CEO | — | 4 patents Stabilized engrailed protein formulations for therapeutic and diagnostic aqueous applications | — |
| 33 | Kinnov Therapeutics Developer of therapies for treating addiction | $3M | 56 mo ago | Funding Raised | — | Philippe Bernard CEO | — | — | — |
| 34 | Op2Lysis Provider of drugs for treating neurology diseases | $3M | 47 mo ago | Funding Raised | 9 | Christophe Gaudin Co-Founder | — | 7 patents Sustained-release fibrinolytic (plasminogen activator) formulations for thrombotic/hemorrhagic therapy | — |
| 35 | Biophytis Developer of drugs for neuromuscular and age-related diseases 45Patents top 32%Moat top 35%Funding top 37%Innovation top 38% All 10 signals ▾Patentstop 32% Moattop 35% Fundingtop 37% Innovationtop 38% Globaltop 45% Partnerstop 45% Newstop 46% Growthbottom 47% Techbottom 43% Marketbottom 42% Patents: 175 patents matched (strict assignee match) · 62 filings since 2022 vs 105 in 2017-21 Moat: Editorial + unicorn rating 5/10 · IP moat: 175 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $3M | 3 mo ago | Public | 24 | — | WordPressPleskMySQL+21 | 175 patents Phytoecdysteroid-based therapeutics for muscle, metabolic, respiratory, and ocular disorders | 1 expansion |
| 36 | Hunt X Pharma Developer of therapeutics for neurological diseases | $2M | 21 mo ago | Seed | — | Frederic Saludo Co-Founder | — | — | — |
| 37 | Mensia Technologies A non-invasive device for the treatment of ADHD | $2M | 81 mo ago | Deadpooled | 20 | Michel du Peloux CEO | — | — | — |
| 38 | InBrain Pharma Developer of therapeutic solutions for the treatment of neurodegenerative diseases | $1M | 13 mo ago | Seed | 4 | Matthieu Fisichella Co-Founder & CEO | — | — | — |
| 39 | Dessintey Developer of intensive rehabilitation technologies designed to accelerate patient return to autonomy | $1M | 84 mo ago | Seed | 18 | Pascal Giraux Co-Founder | WordPressMySQLPHP+22 | 23 patents Neurorehabilitation devices for upper and lower limb motor and cognitive therapy | — |
| 40 | Brain Vectis Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease | $1M | 117 mo ago | Acqui-Hired | 5 | — | — | — | — |
| 41 | Neurallys Developing a device for the treatment of Hydrocephalus | $847K | 86 mo ago | Seed | 3 | Philippe Auvray Co-Founder & CEO | — | 11 patents Neurofluid monitoring devices for CSF turbidity measurement and shunt malfunction detection | — |
| 42 | Mapreg Developer of drug to treat neuronal pathologies | $505K | 189 mo ago | Funding Raised | 10 | Koichi Murakami Founder | — | 33 patents Neuroactive steroid (pregnenolone) derivatives for treating depression and substance‑use disorders | — |
| 43 | Suricog Provider of eye-tracking solutions for diagnosis and monitoring of neurological disorders | $484K | 137 mo ago | Funding Raised | — | Marc Massonneau Co-Founder & Owner & CEO | — | 25 patents Ocular biometric measurement and eye‑tracking technologies for diagnostic and interactive applications. | — |
| 44 | Seenel Imaging Developer of neuroimaging devices to manage neurological disorders | $465K | 65 mo ago | Funding Raised | 8 | Thomas Fontaine Founder & CEO | — | 6 patents Obstetric fetal monitoring devices using intrapartum near‑infrared spectroscopy probes | — |
| 45 | NeoNeuro Provider of aptamer-based molecular diagnostics for Alzheimer's Disease | $363K | 69 mo ago | Seed | — | Gregory Penner Founder & President | — | 6 patents Aptamer-based biomarker discovery for early Alzheimer's disease diagnostics | — |
| 46 | Panaxium Developer of medical equipment for surgeons and neurologists to treat brain injuries | $191K | 6 mo ago | Seed | 22 | Brad Schmidt Founder & CEO | — | 3 patents Implantable biomedical devices for tissue interfacing and stimulation | 1 award |
| 47 | AmyPore Developer of chimeric peptide for neurodegenerative diseases | $111K | 78 mo ago | Funding Raised | 24 | — | — | — | — |
| 48 | SigmaThera Developer of therapeutics to treat neurodegenerative diseases | $111K | 72 mo ago | Funding Raised | — | Francois Roman CEO | — | — | — |
| 49 | Alzohis Non-invasive diagnostics for neurodegenerative diseases | $110K | 74 mo ago | Funding Raised | 5 | Myriam Taverna Co-Founder & CSO | — | 10 patents Computational diagnostic tools for neurodegenerative disease differential diagnosis using biomarkers | — |
Top 12 Neurology companies in France
#1
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Public · Paris, Ile de France · founded 2001 · 3 employees
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 28%Moat
top 28%News
top 33%Growth
top 45%Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) · Last round Post IPO (May 2026)
Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 · Latest publication 2025
Innovation: 461 patents (top 5% of patent-holders) · 78 filings since 2022 vs 86 in 2017-21
Funding rounds
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
Tech stack
Contact Form 7Core-JsGoogle AnalyticsGoogle Font ApiGsapIsotope
#2
Series A · Paris, Ile de France · founded 2017$165Mraised▾
Series A · Paris, Ile de France · founded 2017
Developer of novel medicines for mental health conditions. The company focuses on neuropsychiatric treatments rooted in clinically validated mechanisms. It advances programs for schizophrenia, psychotic disorders, major depressive disorder, and bipolar depression. The lead program is a dual agonist in Phase 1 development. Another program is a novel antagonist currently in IND-enabling studies.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 20%Global
top 45%Talent
bottom 49%Tech
bottom 29%Market
bottom 25%Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Global: Investors from 3 countries beyond France
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -2 · hiring: Chemistry Lead (R&D), CMCL Lead
Funding rounds
- Dec 2025Series A$165M
Founders & team
Investors
Dexcel, Third Rock Ventures, Bain Capital Life Sciences, Google Ventures, QVT Family Office, Pictet Group
Tech stack
Core-JsElementorGoogle Font ApiHello ElementorJqueryJquery Migrate
#3
Public · Romainville, Ile de France · founded 2006 · 24 employees$2.6Mraised▾
Public · Romainville, Ile de France · founded 2006 · 24 employees
Developer of drugs for neuromuscular and age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Other drug candidate, Macuneos (BIO201) for the treatment of retinal diseases, including dry AMD and Stargardt disease.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Patents
top 32%Moat
top 35%Funding
top 37%Innovation
top 38%Global
top 45%Partners
top 45%Patents: 175 patents matched (strict assignee match) · 62 filings since 2022 vs 105 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 175 patents · 10 curated direct competitors tracked
Funding: Raised $2.6M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) · Last round Post IPO (Mar 2026)
Audience (LinkedIn): 5k LinkedIn followers — 3.4% of this cohort's audience
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Mar 2026Post IPO$1.6M
- Jun 2021Post IPO$38.2M
- Jul 2020Post IPO$6.9M
- Oct 2017Post IPO$12.3M
Investors
Seventure Partners, CM-CIC Capital Prive, Kreos Capital
Tech stack
Apple Icloud MailCore-JsElementorGoogle AnalyticsGsapIsotope
#4
Series A · Marseille, France · founded 2020$14.1Mraised▾
Series A · Marseille, France · founded 2020
Developer of therapeutics for the treatment of chronic postoperative and neuropathic pain
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Growth
top 35%Funding
top 47%Talent
bottom 49%Global
bottom 29%Tech
bottom 28%Market
bottom 25%Growth: Fresh capital in last 24 mo
Funding: Raised $14.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Sep 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 3k LinkedIn followers — 2.0% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Sep 2025Series A$14.1M
Founders & team
Investors
Bpifrance, European Innovation Council
Tech stack
Apple Icloud MailMicrosoft 365MysqlOpen GraphPhpPriority Hints
#5
Series B · Paris, Ile de France · founded 2014 · 34 employees$44Mraised▾
Series B · Paris, Ile de France · founded 2014 · 34 employees
Developer of gene therapy for ocular and neurological disease. The drug candidates include CTx-PDE6b for inherited retinal dystrophy, CTx-ABCA4 for Stargardt’s Disease, CTx-GBA1 for Parkinson’s, and neuronopathic Gaucher diseases. These drugs are based on the AAV-ligand conjugates platform for targeted delivery.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 33%Patents
top 34%Growth
top 35%Moat
top 36%Innovation
top 42%Talent
bottom 49%Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series B (Jan 2025)
Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 7k LinkedIn followers — 4.7% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2025Series B$33M
- Jul 2021Series B$39M
- Jul 2016Series A$4.4M
- Jul 2015Grant (prize money)$166.6K
Founders & team
Investors
Omnes Capital, Sham, GO CAPITAL, Ministry of Higher Education and Research, Seroba Life Sciences, Thea Open Innovation
Tech stack
Apple Icloud MailChart.JsComplianzContact Form 7Font AwesomeGoogle Font Api
#6
Seed · Roscoff, Brittany · founded 2019 · 8 employees$6Mraised▾
Seed · Roscoff, Brittany · founded 2019 · 8 employees
Developer of small-molecule drugs that simultaneously inhibit necroptosis and ferroptosis. The lead candidates can treat the acute hepatic failure caused due to paracetamol poisoning and acute renal failure due to side effects of cancer treatment. Other candidates are developed to treat age-related macular degeneration, Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases. The drug candidates are of marine origin and have the ability to simultaneously block two forms of regulated cell death and therefore protect the attacked organs and restore the tissues and organs.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 28%Growth
top 35%Patents
top 42%Moat
top 42%Innovation
bottom 49%Tech
bottom 47%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Growth: Fresh capital in last 24 mo
Patents: 10 patents matched (strict assignee match) · 10 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Oct 2025Seed$2.3M
- Sep 2023Seed$1.3M
- Jul 2023Grant (prize money)$81.9K
- Mar 2022Seed$1.8M
Founders & team
Investors
Bpifrance, Breizh Angels, Europa, iXLife Capital, Breizh Angel, Angels Sante
Tech stack
Apache Http ServerCore-JsElement UiElementorFont AwesomeFormidable Form
#7
Seed · Strasbourg, Grand Est · founded 2025$12.8Mraised▾
Seed · Strasbourg, Grand Est · founded 2025
Developer of innovative antidepressant treatment, accessible, fast-acting, and free from dependence. It focuses on developing a novel neuroplastogen with a mechanism of action able to induce neuroplasticity without the side effects of psychedelics. The company targets intracellular events and neuroplasticity, acting on a highly selective signaling pathway within neurons in key brain circuits. It is dedicated to advancing psychiatric treatments through precision medicine.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 38%Funding
top 44%Global
top 45%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $12.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jun 2025)
Global: Investors from 3 countries beyond France
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Jun 2025Seed$12.8M
Founders & team
Investors
Kurma Partners, Angelini Ventures, Wallonie Entreprendre, Argobio, Bpifrance, CARMA FUND
#8
Seed · Paris, Ile de France · founded 2017 · 15 employees$28Mraised▾
Seed · Paris, Ile de France · founded 2017 · 15 employees
Developer of microrobots for neurosurgical applications. The platform utilizes miniature robots to diagnose, treat, and monitor brain diseases with high precision. It aims to improve patient outcomes and advance the field of neurosurgery and for the treatment of various brain-related disorders. It is used for tasks like biopsies, drug delivery, electrode implantation, and real‑time data collection through complex 3D brain paths.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Growth
top 35%Talent
top 38%Funding
top 44%Global
bottom 39%Tech
bottom 38%Market
bottom 27%Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $28.0M across 1 rounds · 1 rounds over 6 yrs (0.2/yr) · Last round Seed (Jan 2025)
Funding rounds
- Jan 2025Seed$28M
- Jun 2020Grant (prize money)—
Founders & team
Investors
EIT Health, Plural, Kindred Ventures, Cherry Ventures, LocalGlobe, Think.Health
Tech stack
Apple Icloud MailCloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#9
Series B · Paris, Ile de France · founded 2020 · 17 employees$20Mraised▾
Series B · Paris, Ile de France · founded 2020 · 17 employees
Developer of gene therapies for neurogenic bladder. The company has an HSV-1 vector platform for the delivery and expression of a transgene encoding the light chain of botulinum toxin F in sensory neurons to treat neurogenic bladder after spinal cord injury, overactive bladder, and Interstitial cystitis.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 37%Funding
top 38%Moat
top 39%Innovation
top 48%Global
bottom 43%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding: Raised $20.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series B (Feb 2025)
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Feb 2025Series B$28.2M
- Jul 2023Series A$20M
Founders & team
Investors
Andera Partners, Bpifrance, SCI Ventures
Tech stack
Alpine.JsCloudflareCloudflare Browser InsightsGoogle Font ApiHttp/3Jsdelivr
#10
Series A · Villeneuve d Ascq, Hauts de France · founded 2020 · 14 employees$7.4Mraised▾
Series A · Villeneuve d Ascq, Hauts de France · founded 2020 · 14 employees
Developer of therapeutic solutions for the treatment of cancer. The company is focusing on the development of innovative therapeutics by combining drugs and photonic systems to address oncology fields such as brain tumors and glioblastomas (GBM).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.9% of this cohort's audience
Activity: 1 partnerships (incl. American Association of Neurological Surgeons (AANS)) announced in 12 mo
Funding rounds
- Jun 2025Series A$7.4M
Founders & team
Investors
Nord France Amorquage, Finovam Gestion, Capital Cell, Bpifrance
Tech stack
CdnjsCloudflareCookieyesCore-JsGeneratepressGoogle Analytics
#11
Acquired · Saint Cloud, Ile de France · founded 1977 · 1500 employees$248.1Mraised▾
Acquired · Saint Cloud, Ile de France · founded 1977 · 1500 employees
Ethypharm is developing drugs and drug delivery systems (DDS) to treat pain and addiction. The company has developed a drug portfolio such as Morphine, Fentanyl, Tramadol, oxycodone, oxycodone hydrochloride, Etodolac-Lodine, Triamcinolone Hexacetonide, and Episil for treating pain. The company is also developing drugs for alcohol dependence, overdose, and opioid replacement.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 83k LinkedIn followers — 55.4% of this cohort's audience
Founders & team
Investors
Astorg Partners, Biovail, J P Morgan, Goldman Sachs, Economy And Finance, CDC International Capital
Tech stack
Apple Icloud MailCore-JsDocusignGsapHstsJquery
#12
Series B · Paris, Ile de France · founded 2014 · 340 employees$121Mraised▾
Series B · Paris, Ile de France · founded 2014 · 340 employees
Provider of smart healthcare solutions for sleep and EEG lab management. The company offers a comprehensive software solution that enables healthcare providers to manage sleep and EEG labs, with features such as scheduling, HST processing, and remote patient communication. Also, it offers ICECAP an EEG device for inpatient or outpatient testing.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Moat
top 19%Tech
top 25%Patents
top 29%Innovation
top 34%Funding
top 34%Market
top 45%Moat: Editorial + unicorn rating 8/10 · IP moat: 140 patents · Soonicorn
Tech: 53 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx, Varnish
Patents: 140 patents matched (strict assignee match) · 24 filings since 2022 vs 108 in 2017-21 · Latest publication 2025
Funding rounds
- Nov 2023PE$25.6M
- Jun 2019Series B$74M
- Sep 2017Series A$18M
- Jun 2015Seed$3.4M
Investors
LBO France, Idinvest Partners, Dassault Systems, Bpifrance, Kurma Partners, Jolt Capital
Tech stack
Amazon AlbAmazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesAnimate.Css
Funding & investor landscape
$1.1Btotal disclosed funding
50companies funded
118disclosed rounds
1rounds last 90 days
Most active investors
Bpifrance18 rounds
Notable founders
Elisabeth Kogan
Co-Founder & CEO · Syremis
Eric Schettini
Founder & President · Tafalgie
Rodolphe Clerval
Chief Executive Officer · Coave Therapeutics
Marie-Therese Dimanche-Boitrel
Co-Founder · Seabelife
Stephane Bach
Co-Founder · Seabelife
Delphine Charvin
CEO & Co-Founder & Director · Elkedonia
Melanie Rouillier
Co-Founder · Elkedonia
Joana Cartocci
Co-Founder & COO · Robeauté
Bertrand Duplat
CEO · Robeauté
Pierre Denys
Co-Founder · EG 427
Charles Joussain
Co-Founder · EG 427
Maximilien Vermandel
Co-Founder & CEO · Hemerion
Prism market signals · France · country-scoped Prism corpus, 1,992,126 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Neurology companies are there in France?
Radar tracks 99 indexable Neurology companies headquartered in France that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in France?
The Neurology companies in France on this list have raised a combined $1.1B in disclosed equity funding across 50 funded companies.
Which is the highest-funded Neurology company in France?
Ethypharm is the highest-funded Neurology company in France, with $248.1M in disclosed equity funding.
How many Neurology companies in France are funded?
50 of the 99 Neurology companies in France on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in France?
None of the Neurology companies in France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in France Neurology companies?
The most active investors in France Neurology companies on this list include Bpifrance, Europa, EIC Fund, Turenne Groupe, EIT Health.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.